ReviewWorld journal of urology2007
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
Review in World journal of urology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.PloS one · 2012Pooled it
- Detection of a group of classic serum tumor markers (CSTMs) aids in the differential diagnosis and disease assessment of upper tract urothelial carcinoma (UTUC).Translational andrology and urology · 2026Article
- Article
- Review
- Prophylactic role of artemisinin in modulating FGFR3, HRAS, and TP53 to prevent early-stage urothelial carcinoma in BBN-induced mouse models.BMC biotechnology · 2025Article
- Clear cell urothelial carcinoma: a rare but villainous and hostile subtype.American journal of clinical and experimental urology · 2025Article
- Article
- The roles of FGFR3 and c-MYC in urothelial bladder cancer.Discover oncology · 2024Review
- Oncogenic alterations in advanced NSCLC: a molecular super-highway.Biomarker research · 2024Review
- Review
- Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions.International journal of molecular sciences · 2021Review
- The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development.International journal of molecular sciences · 2021Review
- Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer.Journal of personalized medicine · 2021Review
- Lynch Syndrome: Its Impact on Urothelial Carcinoma.International journal of molecular sciences · 2021Review
- The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.Translational cancer research · 2020Review
- FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.International journal of molecular sciences · 2020Review
- A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC).BMC medical genetics · 2020Article
- Article
- Analysis ofMedical journal of the Islamic Republic of Iran · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Although non-invasive bladder tumours (pTa) are the most common group of bladder tumours at presentation, there has until recently been relatively little information on their molecular biology. Thus it was of great interest when mutations in the FGF receptor 3 (FGFR3) were identified in bladder tumours and it became apparent that these were most common in tumours of low grade and stage. Since the initial description of activating mutations of FGFR3, there have been numerous studies confirming the frequency and spectrum of these mutations in bladder cancers of all grades and stages. Mutation screening techniques have evolved and improved. FGFR3 mutation has been assessed as a predictive biomarker in tumour tissues and as a diagnostic biomarker in urine. Efforts have been made to understand the function of FGFR3 in urothelial and other cells. Although our understanding of FGFR3 function is incomplete, it is already apparent that this may represent an important therapeutic target not only in non-invasive bladder cancer but also in a significant number of invasive tumours. This review summarises the current state of knowledge of this interesting receptor in urothelial carcinoma (UC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.